Preview

Онкогематология

Расширенный поиск

Сравнительная эффективность и переносимость липидного комплекса амфотерицина B и липосомального амфотерицина B при лечении инвазивных грибковых инфекций у онкогематологических больных: обзор литературы

https://doi.org/10.17650/1818-8346-2014-9-1-35-41

Полный текст:

Аннотация

Представлен обзор литературных данных, касающихся сравнения токсичности, эффективности и стоимости лечения при использовании липидного комплекса амфотерицина B и липосомального амфотерицина B, а также их сравнения с амфотерицином B дезоксихолатом.

Об авторах

Н. В. Дмитриева
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН
Россия
Лаборатория микробиологической диагностики и лечения инфекций в онкологии


И. Н. Петухова
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН
Россия
Лаборатория микробиологической диагностики и лечения инфекций в онкологии


Список литературы

1. Pagona L., Caira M., Candoni A. et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Hematologica 2006;91:1068–75.

2. Richardson M., Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008;14(Suppl 4):5–24.

3. Morgan J., Wannenmuehler K.A., Marr K.A. et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43(Suppl 1):S49–58.

4. Rex J.H., Stevens D.A. Systemic antifungal agents. Chapter 40. In: Mandell, Douglas and Bennett`s Principles and Practice of Infectious Diseases, 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (eds.). Churchill Livingstone – Elsevier, 2010. Vol. 1, pp. 549–563.

5. Mehta J. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphothericin B preparations? Leuk Res 1997;21:183–8.

6. Schlemmer F., Lagrange-Xelot M., Lacroix C. et al. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogenic stem cell transplantation. Bone Marrow Transplant 2008;42:551–2.

7. Trifillo S., Singhal S., Williams S. et al. Breakthrough fungal infections after allogeneic hematoipoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451–6.

8. Madureira A., Bergeron A., Lacroix C. et al. Breakthrough invasive aspergillosis in allogeneic hematopoietic stem cell transplant recepients treated with caspofungin. Int J Antimicrob Agents 2007;30:551–4.

9. Bowden R., Chandrasekar P., White M.H. et al. A double-blind, randomized, controlled trial of amphoithericin B colloidal dispersion versus amphothericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359–66.

10. Clark A.D., Mc Kendrick S., Tansey P.J. et al. A comparative analysis of lipidcomplexed and liposomal amphothericin B preparations in haematological oncology. Br J Haematol 1998;103:198–204.

11. Smith P.J., Olson J.A., Constable D. et al. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphothericin B. J Antimicrob Chemother 2007;59:941–51.

12. Clark J.M., Whitney R.R., Olsen S.J. et al. Amphothericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615–21.

13. Olson J.A., Adler-Moore J.P., Schwartz J. et al. Comparative efficacies, toxicities and tissue concentrations of amphothericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006;50:2122–31.

14. Paterson P., Seaton S., Prentice H.G. et al. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphothericin B. J Antimicrob Chemother 2003;52:873–6.

15. Janoff A.S., Perkins W.R., Saletan S.L. et al. Amphothericin B lipid complex (ABLC™): a molecular rationale for the attenuation of amphothericin B related toxicities. J Liposome Res 1993;3:451–71.

16. Дмитриева Н.В., Петухова И.Н. Нежелательные явления, наблюдаемые при использовании современных противогрибковых препаратов в лечении инвазивных микозов. Онкогематология2013;2:47–60.

17. Dodds Ashley E., Lewis R., Lewis J. et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:28–39.

18. Sau K., Mambula S.S., Latz E. et al. The antifungal drug amphothericin B promotes inflammatory cytokine release by a toll-like receptor and CD14-dependent mechanism. J Biol Chem 2003;278:37561–8.

19. Malani P.N., Depestel D.D., Riddell J. et al. Experience with community-based amphothericin B infusion therapy. Pharmacotherapy 2005;25:690–7.

20. Craddock C., Anson J., Chu P. et al. Best practice guidelines for the management of adverse events associated with amphothericin B lipid complex. Expert Opin Drug Saf 2009;9:139–47.

21. Laniado-Laborin R., Cabrales-Vargas M.N. Amphothericin B: side effects and toxicity. Rev Iberoam Micol 2009;26(4): 223–7.

22. Klepser M. The value of amphothericin B in the treatment of invasive fungal infections. J Crit Care 2011;26:225–35.

23. Fisher M.A., Tailor G.H., Maislin G. et al. Risk factors for amphothericin B-associated nephrotoxicity. Am J Med 1989;87:547–52.

24. Wingard J.R., White M.H., Anassie E. et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphothericin B versus amphothericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155–63.

25. Olin J.L., Spooner L.M. Amphothericin Bassociated hyperbilirubinemia: case report and review of the literature. Pharmacotherapy 2006;26:1011–7.

26. Walsh T.J., Finberg R.W., Arndt C. et al. Liposomal amphothericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764–71.

27. Mehta J., Blake J., Craddock C. Comparative efficacy of amphothericin B lipid complex and liposomal amphothericin B for the treatment of invasive fungal infections in HSCT recipients and other immunocompromised patient populations with hematologic malignancies: a critical review.

28. Open Transplant J 2011;5:23–9.

29. Slain D., Miller K., Khakoo R. et al. Infrequent occurrence of amphothericin B lipid omplexassociated nephrotoxicity in various clinical settings at a university hospital: a retrospective study. Clin Ther 2002;24(10):1636–42.

30. Deray G. Amphothericin B nephrotoxicity. J Antimicrob Chemother 2002;49(Suppl 1):37–41. 30. Andes D., Safdar N., Marchillo K., Conklin R. Pharmacokineticpharmacodynamic comparison of

31. amphothericin B (AMB) and two lipidassociated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006;50:674–84.

32. Wang J.L., Chang C.-H., Young-Xu Y., Chan K.A. Systematic review and metaanalysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 2010;54:2409–19.

33. Kleinberg M. What is the current and future status of conventional amphothericin B? Int J Antimicrob Agents 2006;26S:12–6.

34. Вarrett J.P., Vardulaki K.A., Conlon C. et al. A systematic review of the fungal effectiveness and tolerability of amphothericin B formulations. Clin Ther 2003;25:1295–320.

35. Cannon J.P., Garey K.W., Danziger L.H. A prospective and retrospectiuve analysis of the nephrotoxicity and efficacy of lipoid-based amphothericin B formulations. Pharmacotherapy 2001;21:1107–14.

36. Fleming R.V., Kantarjian H.M., Husni R. et al. Comparison of amphothericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511–20.

37. Mattiuzzi G.N., Kantrjian H., Faderi S. et al. Amphothericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;100:581–9.

38. Wilson L.S., Reyes C.M., Stolpman M. et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26–34.

39. Martino R. Efficacy, safety and costeffectiveness of Amphothericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004;20:485–504.

40. Kuti J.L., Kotapati S., Williams P. et al. Pharmacoeconomic analysis of amphothericin B lipid complex versus liposomal amphothericin B in the reatment of fungal infections. Pharmacoeconomics 2004;22:301–10.


Для цитирования:


Дмитриева Н.В., Петухова И.Н. Сравнительная эффективность и переносимость липидного комплекса амфотерицина B и липосомального амфотерицина B при лечении инвазивных грибковых инфекций у онкогематологических больных: обзор литературы. Онкогематология. 2014;9(1):35-41. https://doi.org/10.17650/1818-8346-2014-9-1-35-41

For citation:


Dmitrieva N.V., Petukhova I.N. Comparative efficacy and tolerability of amphotericin B lipid complex and liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematological malignancies: literature review. Oncohematology. 2014;9(1):35-41. (In Russ.) https://doi.org/10.17650/1818-8346-2014-9-1-35-41

Просмотров: 568


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)